Neurogene Inc. Contractual Obligation, to be Paid, Year One
Neurogene Inc. (NGNE) had Contractual Obligation, to be Paid, Year One of $234.00 thousand as of 2024-06-30, per its 10-Q filed 2024-08-09.
Discontinued › Notes › Commitment and Contingencies › Contractual Obligation, Fiscal Year Maturity
us-gaap:ContractualObligationDueInNextTwelveMonths · last filed 2024-08-09
- 2024-06-30: Contractual Obligation, to be Paid, Year One $234.00K.
- 2024-03-31: Contractual Obligation, to be Paid, Year One $281.00K.
- 2023-12-31: Contractual Obligation, to be Paid, Year One $281.00K.
| Period end | Contractual Obligation, to be Paid, Year One |
|---|---|
| 2024-06-30 | $234.00K 10-Q · filed 2024-08-09 |
| 2024-03-31 | $281.00K 10-Q · filed 2024-05-10 |
| 2023-12-31 | $281.00K 10-K · filed 2024-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |